|
KR102221856B1
|
|
Novel crystalline polymorph of fimasartan
|
|
KR102222784B1
|
|
Nover edoxaban hemi ethane-1,2-disulfonic acid salt monohydrate
|
|
KR102215623B1
|
|
Novel cocrystal of sacubitril calcium/valsartan and sacubitril/valsartan
|
|
KR102218323B1
|
|
Efficient method for preparing an amorphous empagliflozin without phase transition
|
|
KR102215625B1
|
|
The polymorph of a nover edoxaban hemi naphthalene-1,5-disulfonic acid salt
|
|
KR102209701B1
|
|
A novel crystalline form of tofacitinib, method for prepating thereof
|
|
KR102155474B1
|
|
A novel co-amorphous of sacubitril/valsartan
|
|
KR102150825B1
|
|
Novel sglt-2 inhibitors cocrystal
|
|
KR102149126B1
|
|
A novel cocrystal of sacubitril calcium / valsartan
|
|
KR102207319B1
|
|
New Empagliflozin cocrystal
|
|
KR102111248B1
|
|
New Empagliflozin cocrystal
|
|
KR102090912B1
|
|
The edoxaban a novel crystalline form and the manufacturing method thereof
|
|
KR102097250B1
|
|
A New Crystal form of Ipragliflozin, Method for Preparing or Use Thereof
|
|
KR102111247B1
|
|
Amorphous state of New dapagliflozin cocrystal or complex
|
|
KR20210017070A
|
|
A New Crystal form of Ticagrelor, Method for Preparing or Use Thereof
|
|
KR102054104B1
|
|
A New salt form of Tenofovir alafenamide, Method for Preparing or Use Thereof
|
|
KR102016952B1
|
|
The antiviral agent comprising a novel crystalline form and the manufacturing method thereof
|
|
KR102147600B1
|
|
The polymorph of a novel dabigatran etexilate hemi-salt and the manufacturing method thereof
|
